This page contains a Flash digital edition of a book.
d. FEATURE


ALUNG:


Improving the global standard of care for acute respiratory failure


By Matthew Pross, Publications Manager


Last year was a banner year for South Side-based ALung Technologies. The local life sciences firm received CE Mark approval and entered select European markets with its Hemolung Respiratory Assist System (RAS), raised a $15.8-million Series B-1 round to support the product launch, and was named the Life Sciences Company of the Year by the Pittsburgh Technology Council’s Tech 50 Awards.


Making 2013 even more memorable for ALung was the fact that the product launch was the culmination of a 13-year journey that began when the company spun out of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine in 2000. After two product iterations and years of clinical trials, the Hemolung RAS is now providing Respiratory Dialysis®


to


intensive care patients with pulmonary diseases who need help breathing. Using a special filter to remove carbon dioxide from a patient’s blood while adding oxygen, the Hemolung RAS allows a patient’s lungs to rest and heal without the invasive and debilitating effects of a ventilator.


“The Hemolung RAS is the first device to provide simple, efficient, low-flow extracorporeal carbon dioxide removal for patients with acute respiratory failure,” Peter DeComo, ALung’s Chairman and CEO, said. “Our device connects to the patient via a catheter placed in either the femoral vein in the leg or jugular vein in the neck and filters their blood through a device that removes carbon dioxide and adds oxygen. Filtering the blood in this way takes some of the hard work off of the patient’s lungs so that they can begin to recover.”


Pete DeComo and ALung are creating a new standard of care for


respiratory failure with the Hemolung Respiratory Assist System.


“Intervention with our artificial lung helps stop the downward spiral of respiratory failure common with the exacerbations of chronic obstructive pulmonary disease (COPD),” he explained. “Traditionally, a breathing tube and ventilator are used to stabilize COPD patients who develop respiratory failure. These treatments are quite invasive, often leaving patients sedated and dependent on the ventilator for a long period of time. The advantage of our device is that it can be applied before the patient reaches the point of needing to be placed on the ventilator. Within two hours on the Hemolung RAS, the patient will be resting comfortably and breathing normally.”


DeComo and the ALung team spent 2013 building out a reference center program to gain traction in the European market. As part of this strategy, ALung targeted influential medical centers around Europe to adopt the Hemolung RAS in their intensive care units.


“Any time the standard of care radically changes, it takes time for treatment practices to catch up to the latest technologies,” DeComo explained. “With our reference center program, we have targeted luminary institutions in the European medical community as the key early adopters of the Hemolung RAS.


14 PITTSBURGH TECHNOLOGY COUNCIL


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56